In September, Sanofi received non-exclusive rights to use Scribe Therapeutics, Inc.’s proprietary CRISPR genome editing technologies and platform of wholly owned enzymes to create ex vivo natural killer cell therapies for cancer. Under the terms of the agreement, Scribe received a $25m up-front payment and is eligible to receive more than $1bn in payments based on development and commercial milestones, as well as tiered royalties on net future sales on any resulting products. (Also see "Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals" - Scrip, 27 September, 2022.)
In the top September M&A by deal value, Novo Nordisk A/S entered into an agreement to acquire Forma...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?